# Ata Oral Estrogen Gh Dose

> Suggests women on oral estrogen replacement receive higher GH doses compared to eugonadal females or males. Triggers when managing GH replacement in a woman on oral estrogen requiring GH therapy (e.g., "female on oral estrogen needing GH replacement").

- Skill: `dromlakhani/ata-oral-estrogen-gh-dose` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/ata-oral-estrogen-gh-dose`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-oral-estrogen-gh-dose/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/ata-oral-estrogen-gh-dose

---


# Increase GH replacement dose for women on oral estrogen therapy

## STEP 1 — Gather Information
Confirm female sex, oral estrogen use (type/dose), GH deficiency status, baseline IGF‑1, current GH dose, and presence of GH‑related symptoms or side effects.

## STEP 2 — Rule In / Rule Out
Is the patient a woman receiving oral estrogen? If yes, proceed to dose adjustment; if no (eugonadal female, male, or transdermal estrogen), follow standard GH dosing protocols.

## STEP 3 — Classify or Stratify
For women on oral estrogen, anticipate up to a 50% higher GH dose may be needed to achieve target IGF‑1 levels due to estrogen‑induced hepatic IGF‑1 suppression.

## STEP 4 — Decide
Start GH at age‑based standard dose (0.2–0.4 mg/d if <60 y, 0.1–0.2 mg/d if ≥60 y) and titrate upward in 0.1–0.2 mg/d increments every 6 weeks, aiming for IGF‑1 in the mid‑ to upper‑normal range while monitoring for adverse effects.

## Clinical Guardrails / Mimics / Pitfalls
Do not assume transdermal estrogen requires dose increase; avoid over‑replacement that causes fluid retention, arthralgia, or insulin resistance; always guide dosing by IGF‑1 and clinical response, not weight alone.

## Concrete Clinical Example
A 45‑year‑old woman on oral estradiol 2 mg/day with GHD begins GH at 0.2 mg/d; after 6 weeks IGF‑1 is low‑normal, dose increased to 0.3 mg/d, IGF‑1 reaches target, and she reports improved energy without side effects.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118